Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Childhood Brain Neoplasm 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neurodegenerative Diseases 1Ischemic Stroke 1Hypoxia 1Hemorrhagic Stroke 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Central Nervous System Vascular Malformations 1Central Nervous System Infections 1Brain Neoplasms 1Brain Injuries 1

Interventions

Positron Emission Tomography Computed Tomography 1Ferrosoferric Oxide 1Atovaquone 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Hypoxia × Ferrosoferric Oxide × Clear all
NCT02466828 2018-04-18

qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.

Sunnybrook Health Sciences Centre

Phase EARLY_PHASE1 Completed
10 enrolled
CNS

Hypoxia, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡